Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2015 1
2016 1
2018 5
2019 2
2020 1
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D. De Martin E, et al. J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427729
The management of hepatic IRAEs was tailored according to the severity of both the biology and histology of liver injury: six patients improved spontaneously; seven received oral corticosteroids at 0.5-1 mg/kg/day; two were maintained on 0.2 mg/kg/day corticosteroids; and one pat …
The management of hepatic IRAEs was tailored according to the severity of both the biology and histology of liver injury: six patients impro …
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C. Sun R, et al. Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041
INTERPRETATION: The radiomic signature of CD8 cells was validated in three independent cohorts. This imaging predictor provided a promising way to predict the immune phenotype of tumours and to infer clinical outcomes for patients with cancer who had been treated with anti …
INTERPRETATION: The radiomic signature of CD8 cells was validated in three independent cohorts. This imaging predictor provided a pro …
[Breaking immune tolerance in cancer].
Desbois M, Champiat S, Chaput N. Desbois M, et al. Bull Cancer. 2015 Jan;102(1):34-52. doi: 10.1016/j.bulcan.2014.12.002. Epub 2015 Jan 13. Bull Cancer. 2015. PMID: 25609492 Review. French.
Over the past decade, several immunomodulators have demonstrated clinical effectiveness, and three of them have already been approved for use in oncology. The development of these immunotherapy approaches presented unique challenges for safety and efficacy, requiring revis …
Over the past decade, several immunomodulators have demonstrated clinical effectiveness, and three of them have already been approved …
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage M, Jones RL, Trent J, Champiat S, Dumont S. Roulleaux Dugage M, et al. Front Immunol. 2021 Aug 20;12:715727. doi: 10.3389/fimmu.2021.715727. eCollection 2021. Front Immunol. 2021. PMID: 34489967 Free PMC article. Review.
There have been few immunotherapy trials with anti-CTLA-4 or anti-PD-L1drugs and available clinical data are not very promising. Based on this comprehensive analysis of TME, we believe three immunotherapeutic strategies must be underlined in GIST. First, patients included …
There have been few immunotherapy trials with anti-CTLA-4 or anti-PD-L1drugs and available clinical data are not very promising. Based on th …
Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA, Oh Y, Lee J, Yu J, Chung LI, Lee Y, Kim L, Hong T, Lee S, Shah Z, Park JH, Yoon SM, Chae YK. Djunadi TA, et al. Clin Lung Cancer. 2024 Mar 16:S1525-7304(24)00036-6. doi: 10.1016/j.cllc.2024.03.001. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38644088
METHODS: Clinical and radiologic data from 121 non-small cell lung cancer (NSCLC) patients with 136 immunotherapy cases were reviewed retrospectively. Three HPD definitions (Champiat et al., HPDc; Saada-Bouzid et al., HPDs; and Ferrara et al., HPDf) were employed. . …
METHODS: Clinical and radiologic data from 121 non-small cell lung cancer (NSCLC) patients with 136 immunotherapy cases were reviewed retros …
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
RESULTS: A total of 12/13 patients enrolled were evaluable for DLT (1 patient withdrew consent prior receiving pembrolizumab). Three patients at 200 mg bid experienced a DLT (grade 3 liver enzymes increase). ...Eight patients died because of cancer progression. Median foll …
RESULTS: A total of 12/13 patients enrolled were evaluable for DLT (1 patient withdrew consent prior receiving pembrolizumab). Three …
Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study.
Hilmi M, Naoun N, Boilève A, Géraud A, Bayle A, Pagès A, Aupomerol M, Rouanne M, Madec FX, Pommeret F, Massard C, Baldini C, Scotté F, Champiat S. Hilmi M, et al. Support Care Cancer. 2022 Dec;30(12):9841-9849. doi: 10.1007/s00520-022-07407-6. Epub 2022 Oct 22. Support Care Cancer. 2022. PMID: 36271944 Clinical Trial.
Supportive care needs, QoL (EORTC QLQ-C30) and sexuality (female sexual function index for women, male sexual health questionnaire [MSHQ] for men) were assessed at baseline, one, three and 5 months. We performed multivariate analyses to identify associations between clinic …
Supportive care needs, QoL (EORTC QLQ-C30) and sexuality (female sexual function index for women, male sexual health questionnaire [MSHQ] fo …
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot JM, Massard C, Mezquita L. Pierro M, et al. Cancers (Basel). 2022 Oct 17;14(20):5078. doi: 10.3390/cancers14205078. Cancers (Basel). 2022. PMID: 36291861 Free PMC article.
The primary objective was to study the prognostic role of LIPI score in patients aged 70 years or above in a real-life population treated with anti-programmed death-(ligand)1 (anti PD-(L)1). dNLR and LDH were collected in a prospective cohort of patients aged 70 years or above tr …
The primary objective was to study the prognostic role of LIPI score in patients aged 70 years or above in a real-life population treated wi …
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy.
Belkouchi Y, Talbot H, Lassau N, Lawrance L, Farhane S, Feki-Mkaouar R, Hadchiti J, Dawi L, Vibert J, Cournède PH, Cousteix C, Mazza C, Kind M, Italiano A, Marabelle A, Ammari S, Champiat S. Belkouchi Y, et al. Clin Cancer Res. 2023 Apr 14;29(8):1528-1534. doi: 10.1158/1078-0432.CCR-22-0890. Clin Cancer Res. 2023. PMID: 36719966
The iPD score was constructed using only independent variables, each considered as a worsening factor for the survival of patients. The patients were stratified in three groups: good prognosis (GP), poor prognosis (PP), and critical prognosis (CP). ...
The iPD score was constructed using only independent variables, each considered as a worsening factor for the survival of patients. The pati …
Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study.
Curty G, Beckerle GA, Iñiguez LP, Furler RL, de Carvalho PS, Marston JL, Champiat S, Heymann JJ, Ormsby CE, Reyes-Terán G, Soares MA, Nixon DF, Bendall ML, Leal FE, de Mulder Rougvie M. Curty G, et al. Front Oncol. 2020 Oct 22;10:553983. doi: 10.3389/fonc.2020.553983. eCollection 2020. Front Oncol. 2020. PMID: 33194615 Free PMC article.
The RNA-seq analysis shows 185 differentially expressed genes: 181 host genes (178 upregulated and three downregulated) and four upregulated HERV transcripts in HIV-positive samples. ...
The RNA-seq analysis shows 185 differentially expressed genes: 181 host genes (178 upregulated and three downregulated) and four upre …
16 results